http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0244473-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7aa001f3235c07b0298867908d45e21 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-824 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate | 1986-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f980fdb5711e776f245b2c3861b30c8 |
| publicationDate | 1987-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0244473-A1 |
| titleOfInvention | Method of assaying the presence of cancer cells |
| abstract | A method detects and/or determines the presence of cancer cells in mammals, including humans, and monitors the progress of cancer treatment. A human marker protein, the analytical marker having a molecular weight between 70,000 and 74,000, has been found to be secreted by cancer cells in amounts ten times or more than the amounts observed in normal cells. In an assay, the assay tag or an antigenically analogous protein, the analog tag, is used to prepare antibodies to the assay tag. The antibodies are then reacted with blood or serum samples to determine the level of the assay marker in the sample. The analysis essentially comprises (1) the formation of an antibody to the protein described above; (2) reacting the antibody obtained in step (1) with the sample to be tested and (3) measuring the level of antibody having reacted to the marker in order to detect and/or determine the presence and /or the amount of cancer cells. |
| priorityDate | 1985-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.